Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...
Mathematical thinking is crucial in all areas of computer science: algorithms, bioinformatics, computer graphics, data science, machine learning, etc. In this course, we will learn the most important ...
Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results